Introduction
The use of left ventricular assist devices (LVADs) as treatment of advanced heart failure has increased greatly over the last decade, 1 and survival has improved significantly with the newer generation of continuous flow (CF)-LVADs. 2 Even broader use of the technology, however, has remained limited by long-term complications associated with the devices, including stroke, infections relating to the power driveline, arrhythmias, right heart failure, and pump thrombosis requiring pump exchange. Recently HeartMate 3 TM (HM3) left ventricular assist system (LVAS), a new generation, centrifugal CF-LVAD, has been introduced. The pump has potential advantages over prior CF-LVADs such as full magnetic levitation of the rotor, large blood flow gaps ensuring less trauma to blood components, and generation of an artificial pulse (Supplementary material online, Figure S1 ). A European CE approval study and a US randomized trial using HM3 have demonstrated 1-and 2-year survival of 82% and 83%, respectively, and, importantly, elimination of reoperations for pump thrombosis. [3] [4] [5] [6] However, real-world evidence on survival and incidence of adverse events with this new device remain sparse. In particular, it is unclear if the results observed in the patients selected for the initial clinical trials are reproducible when the device is used commercially. Furthermore, little is known about the outcome in terms of functional capacity and quality of life (QOL) after implantation of a HM3. For this purpose ELEVATE, a prospective, predominantly European registry of consecutive, commercial HM3 implants was launched. The primary focus of the registry was to evaluate clinically relevant endpoints in patients in whom a HM3 was implanted in a real-world scenario. The current analysis describes the 6 months survival, incidence of adverse of events, rehospitalizations, and measures of functional capacity and QOL in the largest cohort of patients implanted with a HM3 so far.
Methods

ELEVATE (Evaluating the HeartMate 3 TM with Full MagLev Technology
in a Post-Market Approval Setting, ClinicalTrials.gov Identifier: NCT02497950) is a prospective, observational, multinational registry including patients in whom a HM3 was implanted after commercial approval beginning January 2015 in Kazakhstan and in Europe after CE mark in October 2015. Patients were enrolled consecutively in the participating centres from the date of commercial approval in the region until the sample size of 540 was reached. Small to large volume centres participated in the registry. Patients are followed in the registry for 24 months postimplant or until an outcome (transplanted, explanted for recovery, expired, or withdrawn), whichever occurs first. The registry protocol and informed consent form were approved by each institution's Ethics Committee. The definitions of outcomes and adverse events (INTERMACS definitions) were similar to those used in the CE Mark trial and the MOMENTUM 3 trial, allowing for comparisons with the trials. Both patients with a primary LVAD implantation and patients in whom a HM3 replaced another LVAD were included in the registry.
Patient enrolment
At each centre participating in the ELEVATE registry, consecutive HM3 patients implanted since commercial approval were identified. For patients from whom informed consent was obtained, full data collection in the registry was made. For patients who were not consented prior to implant and expired prior to consenting to participate, only mortality data were obtained in anonymized form (after additional ethics approval). Patients declining participation were excluded from the registry.
Patient management
Patient selection and post-operative management did not follow a specified protocol but was performed at the discretion of the investigators. Recommended anticoagulation after device implantation was vitamin K antagonist (VKA) with an international normalized ratio (INR) target of 2-3 and low dose aspirin (81-100 mg daily). 
Data collection
Statistical analysis
Continuous data are presented as mean with standard deviation or median with interquartile range (IQR) values, unless otherwise specified. Categorical data are reported as frequencies and percentages. Survival data are presented using the Kaplan-Meier product method, and hazard ratios are calculated with univariable Cox proportional hazards modelling. There was no imputation of missing data except for the 6MWT distance. For patients not performing the 6MWT due to heart failure, the distance was imputed as 0 m. Statistical analysis was performed using SAS version 9.3.
Ethics
The study was conducted in accordance with the Declaration of Helsinki. Patients were informed orally and in writing and provided written consent for the data collection. Mid-way through enrolment, it became clear that a proportion of patients had not been included in the Registry because of lack of consent prior to implant (for instance emergency or comatose patients). As exclusion of these patients could constitute a source of bias, all ethics committees were asked for permission to record in anonymized form only outcome information. All ethics committees granted permission to include this anonymized information in the database.
Results
A total of 544 consecutive patients were implanted with a HM3 at the 26 participating centres during the study period. Four patients did not consent to registry participation and were therefore excluded, leaving a total of 540 patients in whom data were collected. Of these 540 patients, full data collection was obtained from 463 patients that received the HM3 as a primary implant and from 19 patients that were implanted with the HM3 as a replacement of another durable LVAD; in 58 patients only outcome data were obtained (anonymized cohort) ( Figure 1 ). The 463 patients who received a primary HM3 implantation are the main focus of this report.
Six-month outcomes after treatment of advanced heart failure
Primary implant cohort
Baseline characteristics of the 463 primary implant patients are seen in Table 1 . The majority of patients were implanted as a bridgeto-transplantation strategy and a third of the patients were in critical cardiogenic shock or 'sliding fast on inotropes' (INTERMACS 1-2). Fifty-four (12%) patients were on temporary mechanical circulatory support at the time of LVAD implantation (extracorporeal membrane oxygenation, intra-aortic balloon pump, or temporary LVAD). Only 30% were not treated with inotropes at the time of implantation. Accordingly, haemodynamic parameters were clearly compromised, as evidenced by low cardiac index and elevated pulmonary vascular pressures. Functional capacity was severely depressed as evaluated by 6MWT and many patients were intolerant of angiotensin converting enzyme inhibitor/angiotensin receptor blocker (ACE-I/ARB) and beta-blockers. End-organ function was impaired as judged by elevated liver function tests and creatinine. Almost 40% had a concomitant cardiac procedure performed at the time of surgery (Supplementary material online, Table S1 ) with the most common was being tricuspid repair (n = 73, 16%) and aortic valve intervention (replacement or over sewing, n = 37, 8%). Median intensive care unit (ICU) stay was 8 (IQR 4-21) days and 92% of the patients were discharged by 6 months after a median length of hospital stay of 29 (IQR 21-46) days. At discharge average pump speed was 5421 ± 390 revolutions per minute (RPM) and pump flow 4.3 ± 0.7 L/min. At 6 months 84% of patients were treated with a VKA plus an antiplatelet agent, whereas 15% were managed with a VKA alone and 1% was treated with heparin. After 6 months of HM3 support, 82% of patients were NYHA Class I or II. Patients also experienced significant improvements (P < 0.001) in 6MWT and QOL ( Figure 2) ; however, only 37-41% of patients of the primary implant cohort contributed with paired data for these analyses. Adverse events reported are listed in Table 2 . Of note, there were no incidences of any pump thrombosis. Stroke was encountered in 25 patients (5.4%) and the majority of these were ischaemic. A total of 196 unplanned rehospitalizations occurred in approximately one-third (32%, 135 of 424) of the discharged patients (0.9 admission per patient year, Figure 3 ). The most common reason for re-hospitalization was infection (n = 52, 27%; Supplementary material online, Table S2 ). The median percentage of time spent out of the hospital was 79% (IQR 63-86%).
Six-month survival in this primary implant cohort was 92% [95% confidence interval (95% CI) 89-94%] with only three patients being transplanted ( Figure 4A ). Predictors of mortality at 6 months 
Full cohort
The 6-month survival in the full cohort was 82% (95% CI 79-85) with only three patients being transplanted and no reports of patients experiencing ventricular recovery ( Figure 4B ). The causes of death can be seen in Table 4 . Irrespective of cohort (primary implant or full), the majority of deaths were due to right heart failure or multiorgan failure, followed by infection/sepsis and then stroke. In one anonymized patient who expired due to cardiac arrest, an ingested pump thrombosis was suspected. In addition, stroke was indicated as the cause of death in five anonymized patients and three patients undergoing HM3 implant as replacement suffered a stroke. Adding these strokes to the analysis results in an incidence of stroke unchanged at 6.1% (33/540).
Discussion
The main findings in the present analysis of the ELEVATE registry are that 6-month survival of patients in whom a HM3 was implanted as a primary implant or exchange from another device in a post-approval trial setting was 82%. The survival did not differ in high volume and low volume participating centres. Further, while adverse events remain common, we are encouraged by the absence of pump thrombosis and the low rate of stroke in this post-approval registry when compared to previous studies of CF-LVADs. Based on the pre-implant haemodynamics, low ejection fraction, use of inotropes or temporary mechanical support, and evidence of endorgan dysfunction the patients enrolled in the ELEVATE registry were clearly in line with the recommendations of the ESC for selecting patients for durable LVAD implantation. 7 As judged by INTERMACS profiles, patients included in ELEVATE were more critically ill than patients included in the HM3 CE Mark study (only 10% INTERMACS 1-2), and while the proportion of patients in INTERMACS 1-2 was similar to that of patients included in the MOMENTUM 3 short-term cohort, more patients in ELEVATE were in the most critical state (INTERMACS 1, 9 vs. 1%). In contrast, patients in the CE Mark study and MOMENTUM 3 trial were slightly older than patients in ELEVATE. 3, 4 Survival in the ELEVATE registry is in line with previous reports of other LVADs and although slightly lower than reported in previous studies of the HM3, 3, 4 it is similar to the recent analysis of patients in the IMACS registry (87%). 2 This difference between ELEVATE and the initial HM3 studies is likely related to selection of sicker patients, even if a significant correlation between INTERMACS profile and outcome could not be demonstrated in the ELEVATE registry. This is to be expected when use of the device is no longer restricted to patients fulfilling inclusion criteria in specified study protocols. In IMACS, 48% were in INTERMACS profile 1-2. 2 Potentially, the initial reports of low incidences of pump thrombosis with the HM3 encouraged ELEVATE investigators to implant high-risk patients they would not have considered for the previously available devices. Comparing strictly with European data, survival in ELEVATE is superior to that recently reported for CF-LVAD in the EUROMACS registry. 8 However, survival rates with the HM3 should be monitored closely in the longer term follow-up of ELEVATE as well as in the long-term MOMENTUM 3 cohort. As seen in previous LVAD studies, adverse events were common and led to frequent hospitalizations. Approximately one-third of discharged patients underwent an unplanned re-hospitalization within 6 months, and this is slightly lower than seen in previous studies. Main causes for re-hospitalization were infection and bleeding, and only few admissions (2%) were due to alarms for driveline communication faults or controller errors. The introduction of an artificial pulse (every 2 s) in the HM3 has not been associated with lower rates of gastrointestinal bleeding than seen with other CF devices. 9 It was hoped that the artificial pulse might prevent formation of arteriovenous malformations in the gastrointestinal tract, which are a main source of bleeding. 10 Also, lower shear stress due to larger gaps in the Table S4 ). 3, 4 Hence, it is possible that the HM3 in the future might allow for less intense anticoagulation protocols likely leading to lower incidences of bleeding events. 14, 15 In this context, one should also consider that a few cases of outflow graft thrombosis have been reported in HM3, although the overall incidence continues to be very low. [16] [17] [18] In one patient in the anonymized cohort, a thrombus obstructing the inflow cannula occurred. In this patient, a thrombus in the left ventricular cavity was found at the time of surgery, and likely the event represented an ingested thrombus. The stroke rate in ELEVATE was low at 5.4%, despite a high prevalence of cerebrovascular events prior to implantation. Several factors that may explain this finding include better medical management with focus on blood pressure management, 19 better surgical techniques, and improved overall haemocompatibility of the HM3 compared to previous CF-LVADs. 20 If the latter factor is real, the lower stroke rate should be evident also in the subsequent long-term analyses of ELEVATE.
As expected, functional status improved considerably in patients undergoing 6MWT both prior to LVAD implantation and after 6 months. The average distance increased by more than 200 m, which is several times higher than that seen after implantation with cardiac resynchronization pacemakers. 21 In accordance, QOL was significantly improved and 82% of the patients alive were in NYHA Class I-II after 6 months. These findings are similar to those reported in the CE Mark study and the MOMENTUM 3 trial.
Limitations
As with all registries, ELEVATE encompasses some limitations. The main limitation is the lack of consent for 62 of the implanted patients, especially since 58 of these patients were not missing randomly but due to death. Importantly, we obtained ethics approval to include information on mortality and time on device in these patients, which enabled us to present accurate survival for 99.3% of all implanted patients. However, adverse event rates could be influenced by lack of information on the 58 patients as they may have experienced more adverse events than the included patients. The large size of the registry does to some extent counteract but not eliminate the importance of this source of bias. ELEVATE has several strengths compared with other registries. First, it provides consecutive, structured prospective information on a real-life cohort of patients treated with the same implanted device. Second, both small and large centres as well as centres new to the technology and very experienced centres have provided data. Third, data in the registry were queried to clarify inconsistencies and missing entries ensuring a high level of reliability.
Conclusions
The ELEVATE registry documents survival in line with previous reports and improved QOL in a large, real-world cohort of patients with advanced HF treated with the novel, fully magnetically levitated HM3 LVAD. The study confirms absence of pump thrombosis at 6 months as seen in two previous smaller trials. Longer term followup will determine if these positive findings are maintained.
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